The Consortium for Food Allergy Research (CoFAR): The first generation
Hugh A Sampson, M Cecilia Berin, Marshall Plaut, Scott H Sicherer, Stacie Jones, A Wesley Burks, Robert Lindblad, Donald Y M Leung, Robert A Wood, Hugh A Sampson, M Cecilia Berin, Marshall Plaut, Scott H Sicherer, Stacie Jones, A Wesley Burks, Robert Lindblad, Donald Y M Leung, Robert A Wood
Abstract
The Consortium for Food Allergy Research (CoFAR) was established by the National Institute of Allergy and Infectious Diseases in 2005 as a collaborative research program bringing together centers focused on the study of food allergy. CoFAR was charged with developing studies to better understand the pathogenesis and natural history of food allergy, as well as potential approaches to the treatment of food allergy. In its first iteration an observational study of infants with milk and egg allergy was established, and studies of oral immunotherapy for egg allergy and sublingual immunotherapy for peanut allergy were initiated, as was a phase 1 study of a recombinant peanut protein vaccine. CoFAR was renewed in 2010 for an additional 5-year period during which the initial observational study was continued, a study of eosinophilic esophagitis was initiated, and new therapeutic trials were established to study epicutaneous immunotherapy for peanut allergy and to compare the safety and efficacy of egg oral immunotherapy to the ingestion of baked egg for the treatment of egg allergy. The results of these efforts will be reviewed in this rostrum, with a brief look to the future of CoFAR.
Keywords: Food allergy; egg allergy; epicutaneous immunotherapy; immunotherapy; oral immunotherapy; peanut allergy; sublingual immunotherapy.
Copyright © 2018 American Academy of Allergy, Asthma & Immunology. All rights reserved.
Figures
Source: PubMed